KOR

e-Article

Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing
Document Type
article
Source
Genes & Development. 29(14)
Subject
Medical Biotechnology
Biomedical and Clinical Sciences
Rare Diseases
Gene Therapy
Digestive Diseases
Genetics
Cancer
Biotechnology
Pancreatic Cancer
Good Health and Well Being
Adenocarcinoma
Animals
Carcinoma
Pancreatic Ductal
Clustered Regularly Interspaced Short Palindromic Repeats
Disease Models
Animal
Gene Expression Regulation
Neoplastic
Genetic Vectors
Genome
Humans
Lentivirus
Mice
Mice
Inbred C57BL
Mice
Transgenic
CRISPR
genome editing
mouse model
pancreatic cancer
Biological Sciences
Medical and Health Sciences
Psychology and Cognitive Sciences
Developmental Biology
Biological sciences
Biomedical and clinical sciences
Psychology
Language
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a genomically diverse, prevalent, and almost invariably fatal malignancy. Although conventional genetically engineered mouse models of human PDAC have been instrumental in understanding pancreatic cancer development, these models are much too labor-intensive, expensive, and slow to perform the extensive molecular analyses needed to adequately understand this disease. Here we demonstrate that retrograde pancreatic ductal injection of either adenoviral-Cre or lentiviral-Cre vectors allows titratable initiation of pancreatic neoplasias that progress into invasive and metastatic PDAC. To enable in vivo CRISPR/Cas9-mediated gene inactivation in the pancreas, we generated a Cre-regulated Cas9 allele and lentiviral vectors that express Cre and a single-guide RNA. CRISPR-mediated targeting of Lkb1 in combination with oncogenic Kras expression led to selection for inactivating genomic alterations, absence of Lkb1 protein, and rapid tumor growth that phenocopied Cre-mediated genetic deletion of Lkb1. This method will transform our ability to rapidly interrogate gene function during the development of this recalcitrant cancer.